C030006K11Rik activators using the information from the chemicalsC030006K11Rik Activators are a diverse set of chemical compounds that facilitate the enhancement of the functional activity of C030006K11Rik through distinct signaling pathways and biochemical mechanisms. Forskolin and IBMX both work by increasing intracellular levels of cAMP, which is a crucial second messenger in cellular signaling. Forskolin achieves this by directly activating adenylate cyclase, while IBMX inhibits phosphodiesterases, preventing the degradation of cAMP and cGMP. The increased cAMP levels activate PKA, potentially leading to the phosphorylation and subsequent activation of C030006K11Rik, assuming that C030006K11Rik is a substrate or is regulated by PKA. Similarly, the ionophore Ionomycin raises intracellular calcium levels, which might activate calcium-sensitive enzymes or kinases in pathways that converge on C030006K11Rik. PMA, as a PKC activator, and Okadaic Acid, a phosphatase inhibitor, promote phosphorylation within the cell, potentially enhancing the activity of C030006K11Rik by affecting the protein's phosphorylation state directly or through downstream signaling cascades.
The activity of C030006K11Rik is further modulated by compounds that influence various cellular signaling mechanisms. Anisomycin activates the JNK pathway, which could lead to the activation of transcription factors responsible for the increased expression or activity of C030006K11Rik. EGCG and LY294002 are kinase inhibitors that may indirectly result in the activation of C030006K11Rik by modulating the signaling landscape. Sphingosine-1-phosphate, through its receptors, initiates signaling that could activate kinases or effectors impacting C030006K11Rik. Tetrodotoxin alters neuronal signaling, which might indirectly upregulate C030006K11Rik activity by changing the signaling milieu. Brefeldin A disrupts protein trafficking, possibly enhancing C030006K11Rik function by modifying protein interactions or localization. Lastly, SB203580, by inhibiting p38 MAPK, might shift signaling in favor of pathways that activate C030006K11Rik, assuming its activity is linked to or regulated by the p38 MAPK pathway. Each activator, through its targeted mechanism, contributes to the enhancement of C030006K11Rik without necessitating a direct interaction with the protein or its gene.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which increases intracellular cAMP and cGMP by preventing their degradation. Elevated cAMP/cGMP levels can activate PKA or PKG, respectively, potentially enhancing the activity of C030006K11Rik through phosphorylation events. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium concentrations. Elevated calcium can activate calmodulin-dependent kinases or other calcium-sensitive enzymes that might directly or indirectly enhance the activity of C030006K11Rik through phosphorylation or allosteric activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). PKC activation can lead to downstream phosphorylation events or alterations in cell signaling pathways that may enhance the functional activity of C030006K11Rik if it is part of or regulated by PKC-dependent pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, leading to an increase in phosphorylation levels within the cell. This inhibition could result in enhanced phosphorylation and activity of C030006K11Rik if it is regulated by these phosphatases. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a potent activator of the stress-activated protein kinases/JNK pathway. Activation of JNK signaling could lead to the phosphorylation and activation of transcription factors that increase the expression of C030006K11Rik or enhance the activity of its protein product. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol found in green tea that has been shown to inhibit certain protein kinases. The inhibition of these kinases could shift cellular signaling in a way that enhances the activity of C030006K11Rik, assuming it is negatively regulated by one or more of these kinases. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors, triggering intracellular signaling pathways. These pathways could lead to the activation of kinases or other proteins that enhance the activity of C030006K11Rik. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which can affect protein trafficking and secretion. If C030006K11Rik is involved in these processes, Brefeldin A could potentially enhance its activity by altering its localization or the availability of interacting proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to changes in the Akt signaling pathway. If C030006K11Rik is regulated by the PI3K/Akt pathway, inhibition of PI3K could lead to a compensatory upregulation or activation of C030006K11Rik. | ||||||